Tarsus Pharmaceuticals, Inc. $TARS Shares Bought by Alps Advisors Inc.

Key Points

• Alps Advisors increased its Tarsus Pharmaceuticals position by 34% in the third quarter, adding 14,765 shares to hold 58,130 shares valued at about $4.57 million.
• Institutional investors own approximately 90% of Tarsus shares. Analysts have a consensus “Moderate Buy” rating and an average price target of $104.57.
• Tarsus reported quarterly revenue of $194.57 million, above estimates, but its loss of $14.40 per share was far wider than the expected $1.46 loss.

Alps Advisors Inc. lifted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 34.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,130 shares of the company's stock after buying an additional 14,765 shares during the quarter. Alps Advisors Inc. owned about 0.12% of Tarsus Pharmaceuticals worth $4,570,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Hsbc Holdings PLC lifted its stake in shares of Tarsus Pharmaceuticals by 295.0% in the 2nd quarter. Hsbc Holdings PLC now owns 38,090 shares of the company's stock valued at $2,429,000 after purchasing an additional 28,447 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at about $7,204,000. Bank of America Corp DE grew its stake in Tarsus Pharmaceuticals by 57.5% during the first quarter. Bank of America Corp DE now owns 1,194,377 shares of the company's stock worth $83,786,000 after purchasing an additional 436,271 shares during the period. TimesSquare Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals during the second quarter worth approximately $23,249,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Tarsus Pharmaceuticals in the second quarter worth approximately $5,726,000. Institutional investors own 90.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on TARS shares. The Goldman Sachs Group started coverage on Tarsus Pharmaceuticals in a research note on Thursday, September 24th. They issued a "buy" rating and a $116.00 price target on the stock. Mizuho reduced their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Guggenheim raised their price objective on shares of Tarsus Pharmaceuticals from $89.00 to $97.00 and gave the stock a "buy" rating in a research report on Thursday. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 13th. Finally, Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a "buy" rating in a research report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $104.57.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Recent coverage highlights record Q3 sales and a raised revenue outlook, supporting the view that commercial momentum is improving. The reported $194.57 million in quarterly revenue also exceeded the cited consensus estimate of $187.83 million. Tarsus Pharmaceuticals Could Be 31% Undervalued Following Record Q3 Sales
• Positive Sentiment: Guggenheim raised its price target to $97 from $89 and maintained a Buy rating. HC Wainwright also kept its Buy rating and $106 target, while raising its FY2027–FY2030 earnings forecasts, suggesting greater confidence in longer-term profitability. Tarsus Pharmaceuticals Stock Gets Price Target Increase from HC Wainwright
• Neutral Sentiment: Tarsus plans to participate in upcoming investor conferences. The announcement may provide opportunities for investor updates but does not disclose a new business or clinical development. Tarsus to Participate in Upcoming Investor Conferences
• Negative Sentiment: HC Wainwright cut its Q4 2026 EPS forecast to a loss of $0.55 from a loss of $0.14, and reduced its FY2026 estimate to a loss of $15.85 from $2.25. Separately, Tarsus reported a Q3 loss of $14.40 per share, substantially wider than the cited $1.46 consensus loss. These figures raise concern about near-term costs and profitability despite revenue growth.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, Director William J. Phd Link sold 12,500 shares of the company's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total transaction of $979,750.00. Following the transaction, the director directly owned 94,487 shares of the company's stock, valued at $7,405,891.06. This represents a 11.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 3,180 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $87.50, for a total transaction of $278,250.00. Following the sale, the insider owned 1,590 shares of the company's stock, valued at $139,125. This trade represents a 66.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 48,031 shares of company stock valued at $4,004,227. Company insiders own 9.64% of the company's stock.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $68.60 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.96 and a quick ratio of 1.94. The company's 50-day moving average is $74.99 and its 200-day moving average is $67.82. The stock has a market capitalization of $3.38 billion, a PE ratio of -4.52 and a beta of 0.34. Tarsus Pharmaceuticals, Inc. has a 1 year low of $53.89 and a 1 year high of $91.53.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($14.40) EPS for the quarter, missing analysts' consensus estimates of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative return on equity of 24.51%. The firm had revenue of $194.57 million during the quarter, compared to the consensus estimate of $187.83 million. Equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -12.10 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for diseases with significant unmet medical needs, particularly in eye care. The company's work includes therapies targeting Demodex mites, microscopic parasites associated with certain eye conditions.

Its lead product, XDEMVY (lotilaner ophthalmic solution), is an FDA-approved prescription treatment for Demodex blepharitis, an eyelid condition. Tarsus has also evaluated lotilaner-based candidates for other conditions, including ocular rosacea and Lyme disease prevention.

Founded in 2016 and based in Irvine, California, Tarsus is led by co-founder, president and chief executive officer Bobak Azamian.

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.